Abstract
Those committed to the free exchange of scientific information have long complained about various restrictions on access to the FDA's pharmaceutical data and the resultant restrictions on open discourse. A review of open-government procedures and litigation at the FDA demonstrates that the need for transparency at the agency extend well beyond the reach of any clinical trial registry.
Citation
Peter Lurie & Allison Zieve,
Sometimes the Silence Can Be like the Thunder: Access to Pharmaceutical Data at the FDA,
69 Law and Contemporary Problems
85-98
(Summer 2006)
Available at: https://scholarship.law.duke.edu/lcp/vol69/iss3/5